The city of Kingwood, Texas, currently has 6 active clinical trials seeking participants for Lung Cancer research studies.
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
NCT05468489
Recruiting
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Lumi Research, Kingwood, Texas
Conditions: Extensive Stage Small Cell Lung Cancer
Register for Updates
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533
Recruiting
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: Research Site, Kingwood, Texas
Conditions: Non-Small Cell Lung Cancer
Register for Updates
GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors
NCT04083599
Recruiting
To evaluate the safety and anti-tumor activity of GEN1042 in patients with metastatic or locally advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Lumi Research, Kingwood, Texas
Conditions: Malignant Solid Tumor, Melanoma, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Ductal Adenocarcinoma (PDAC)
Register for Updates
A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer
NCT04302025
Recruiting
This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors that meet protocol-specified biomarker criteria
Gender:
All
Ages:
18 years and above
Trial Updated:
04/29/2024
Locations: Lumi Research, Kingwood, Texas
Conditions: Non-small Cell Lung Cancer
Register for Updates
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
NCT05353257
Recruiting
This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of Serplulimab + chemotherapy+ concurrent radiotherapy vs chemotherapy+ concurrent radiotherapy in subjects with Limited-Stage Small Cell Lung Cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/29/2024
Locations: Pro Research Tools, INC DBA Lumi Research, Kingwood, Texas
Conditions: Limited-Stage Small Cell Lung Cancer
Register for Updates
Screening for High Frequency Malignant Disease
NCT05117840
Recruiting
The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
04/10/2023
Locations: 3Sync Research, Kingwood, Texas
Conditions: Lung Cancer
Register for Updates